GLP-2 analogues significantly reduced parenteral support volume by 251.51 mL/day in adult patients with .
The analysis included six randomized controlled trials with a total of 454 patients.
A higher proportion of patients in the treatment group responded positively to GLP-2 analogues compared to placebo.
No significant difference in adverse or serious adverse events was observed between the GLP-2 analogue and placebo groups.
Current evidence is limited due to a small number of early clinical trials and variations in dosing regimens.
More extensive phase 3 randomized controlled trials are necessary to confirm the safety and efficacy of GLP-2 analogues.
Simplified
BACKGROUND AND OBJECTIVE: (SBS) is a malabsorptive condition often requiring long-term parenteral support (PS), which is associated with significant complications. (GLP-2) analogues are shown to enhance intestinal adaptation and reduce PS dependency. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of GLP-2 analogues in adult patients with SBS dependent on PS.
METHODS: A systematic search of CENTRAL, PubMed, Embase, ClinicalTrials.gov, and Google Scholar was conducted from inception till May 2025. We included randomized controlled trials (RCTs) comparing GLP-2 analogues with placebo in adult SBS patients on stable PS. We analyzed the outcomes using RevMan 5.4, with risk ratio (RR) and mean differences (MD) as the effect measures.
RESULTS: Six RCTs comprising 454 patients were included. GLP-2 analogues significantly reduced PS volume (MD: -251.51 mL/day; 95% CI: -363.93 to -139.08; = 2.5%). The proportion of responders was significantly higher in the treatment group (RR: 1.97; 95% CI: 1.47-2.64), with no significant difference in adverse or serious adverse events between the two groups. I2
CONCLUSION: Our meta-analysis found that GLP-2 analogues are effective in reducing PS volume in patients with SBS who are dependent on PS, without an increase in adverse events. However, the current evidence is limited by a small number of early clinical trials, heterogeneity in dosing regimens, and a paucity of data on newer agents like glepaglutide. Further large-scale phase 3 RCTs are needed to validate the safety and efficacy of GLP-2 analogues before they can be adopted for routine clinical practice.
Key numbers
-251.51 mL/day
Mean Reduction in Volume
Mean change from baseline in patients treated with .
1.97
Proportion of
comparing to vs. placebo.
1.19
Incidence of Serious
for serious between treatment and placebo groups.
Full Text
We can’t show the full text here under this license.
